Hope for Families Battling Deadly Brain Cancer

Researchers are making crucial progress in understanding and treating diffuse midline gliomas (D.M.G.), a type of brain tumor historically seen as a grim prognosis for affected children and adolescents.

Ethan White first noticed an issue during a drum practice session. As a snare drummer with the University of Michigan’s marching band, he was suddenly unable to feel his right hand gripping the drumstick properly. Weeks earlier, he had been on the field as the Wolverines clinched the 2023 national football championship. His difficulties began escalating; Ethan stumbled while ascending stairs. Following advice from the university’s health service, Ethan consulted a neurologist. In March 2024, at the age of 20, he was diagnosed with D.M.G., known for its aggressive nature, predominantly afflicting children and adolescents yet also impacting adults.

D.M.G. is recognized as the deadliest pediatric cancer. Historically, children with D.M.G. survived for about a year. Treatment options were limited and outcomes were predictable—radiation might slow the tumor temporarily and mitigate symptoms like weakness and double vision, yet mortality ensued soon after.

Recent years have seen notable developments. Researchers identified a genetic mutation key to many D.M.G. cases and have been exploring therapies targeting these mutations. Though not curative, these treatments promise hope by potentially delaying the disease progression in certain patients, with a few individuals surviving for several years.

“For the first time, we don’t see zero survival,” remarked Dr. Sabine Mueller, director of the Pediatric Brain Tumor Center at the University of California, San Francisco. In 2025, the Food and Drug Administration approved the initial drug for D.M.G., offering a glimpse of hope amid ongoing experimental treatments.

Currently, Ethan is receiving hospice care at home, with his parents providing dedicated full-time support.